Haemonetics Corporation
$5.68B- Market cap
- $4.68B
- Debt
- +$1.24B
- Cash
- −$245.44M
Capital structure 79% equity / 21% debt · EV / Revenue 4.26x · EV / EBITDA 21.58x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: HAE stock price at premium vs META $102.92 current versus $53.83 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at META's multiple
Implied fair value · at HAE's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Expensive
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: HAE FY 2026 (ended Mar 28, 2026) · META FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 79% equity / 21% debt · EV / Revenue 4.26x · EV / EBITDA 21.58x
Capital structure 96% equity / 4% debt · EV / Revenue 7.68x · EV / EBITDA 14.66x
META carries the larger enterprise value at $1.54T against $5.68B; HAE trades on the lower EV / Revenue multiple (4.26x vs 7.68x); META on the lower EV / EBITDA (14.66x vs 21.58x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Haemonetics Corporation · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Meta Platforms, Inc. · implied price per share
Bear
$304.64
Base
$371.86
Bull
$424.13
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.56x
0.27x
Net debt / EBITDA
Leverage against operating earnings
3.80x
-0.22x
Cash and equivalents
Liquid reserves on the balance sheet
$245.44M
$81.59B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
$1.24B
$58.74B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.